JAK2 Exon 12 and Other Non-V617F Mutation Detection, Blood
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Aiding in the distinction between a reactive cytosis and a myeloproliferative neoplasm, particularly when a diagnosis of polycythemia is being entertained
This is a second-order test that should be used when the test for the JAK2B / JAK2 V617F Mutation Detection, Blood test is negative.
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
See Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation in Special Instructions
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Mutation Detection in cDNA Using Sanger Sequencing
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
JAK2 Exon 13
JAK2 Exon 14
JAK2 Exon 15
Janus Kinase 2 Gene
Janus Kinase 2 Gene Sequencing
Tyrosine Kinase Gene Sequencing
Tyrosine Kinase Mutuation